Most recent guideline publication:
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012)
Updates since publication:
May 2014 : Guideline authors reviewed additional literature and concluded that none of the evidence would change the therapeutic recommendations in the 2012 guideline; therefore, the 2012 guideline remains clinically current. The guideline supplement and evidence table were updated (see below).
Tables and figure provided in the main manuscript of the guideline:
| Table 1. Assignment of likely HLA-B phenotypes based on genotypes |
| Table 2. Recommended therapeutic use of abacavir in relation to HLA-B genotype |
| Figure 1. Treatment algorithm for clinical use of abacavir based on HLA-B*57:01 genotype |
Supplement to: Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (May 2014)
Tables and figures included in the supplement:
| Supplemental Table S1. Frequencies of alleles in major racial/ethnic groups |
| Supplemental Table S2. Detailed table with all references and clear assignment of racial/ethnic groups |
| Supplemental Table S3. Evidence linking genotype with phenotype |
| Supplementary Figure S1. Nucleotide coding sequence alignment of HLA-B*57:01:01 and the reference sequence HLA-B*07:02:01 |
| Supplementary Figure S2. Amino acid sequence alignment of HLA-B*57:01 and the reference sequence HLA-B*07:02 |
| Supplemental Table S4. Drug(s) that pertain to this guideline |
| Supplemental Table S5. Gene(s) that pertain to this guideline |
| Supplemental Figure S3. HLA-B*57:01 pharmacogenetic test result: clinical implementation workflow for EHR |
| Supplemental Figure S4. HLA-B*57:01 genotype and abacavir: point of care clinical decision support |
| Supplemental Table S6. Translation of genotype test result into interpreted phenotype |
| Supplemental Table S7. Example implementation of this guideline: pharmacogenetic genotype/phenotype summary entries |
| Supplemental Table S8. Example implementation of this guideline: point of care clinical decision support |
Original publication (April 2012):
- Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing
- 2012 supplement
This guideline has been endorsed by the American Society of Health-System Pharmacists (ASHP).